The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Items 301–400 of 802
Kotkowska, Z., & Strzelecki, D. (2022) · Pharmaceuticals · doi:10.3390/ph15040391 · Cited by 98
Simon, M. S., Arteaga-Henríquez, G., Algendy, A. F., Siepmann, T., & Illigens, B. M. W. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s385117 · Cited by 66
Johansson, D., Falk, A., Marcus, M. M., & Svensson, T. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.003 · Cited by 63
Dahl, J., Ormstad, H., Aass, H. C. D., Sandvik, L., Malt, U. F., & Andreassen, O. A. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12576 · Cited by 58
Memon, A. A., Sundquist, K., Ahmad, A., Wang, X., Hedelius, A., & Sundquist, J. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.05.012 · Cited by 59
Inflammation in neurological and psychiatric diseases
Khansari, P. S., & Sperlágh, B. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0124-x · Cited by 66
Roles of multiple lipid mediators in stress and depression
Furuyashiki, T., Akiyama, S., & Kitaoka, S. (2019) · International Immunology · doi:10.1093/intimm/dxz023 · Cited by 59
Halaris, A., Cantos, A., Johnson, K., Hakimi, M., & Sinacore, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.021 · Cited by 56
(2015) · Europe PMC (PubMed Central) · Cited by 58
Carvalho, L. A., Garner, B. A., Dew, T., Fazakerley, H., & Pariante, C. M. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.02.006 · Cited by 56
Glucocorticoids and Inflammation: A Double-Headed Sword in Depression?
Horowitz, M. A., Zunszain, P. A., Anacker, C., Musaelyan, K., & Pariante, C. M. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343980 · Cited by 57
Du, Y., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Fan, N., Yang, X., & Ma, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1407529 · Cited by 66
Maxeiner, H. G., Rojewski, M., Schmitt, A., Tumani, H., Bechter, K., & Schmitt, M. W. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.08.003 · Cited by 66
Kandratavicius, L., Peixoto-Santos, J. E., Monteiro, M. R., Scandiuzzi, R. C., Carlotti, C. G., Assirati, J. A., Hallak, J. E. C., & Leite, J. P. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0266-z · Cited by 59
Moraes, M. M. T., Galvão, M. C., Cabral, D., Coelho, C. P., Queiroz-Hazarbassanov, N., Martins, M. F. M., Bondan, E. F., Bernardi, M. M., & Kirsten, T. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169446 · Cited by 54
Hongxia, L., Yuxiao, T., Zhilei, S., Yan, S., Yicui, Q., Jiamin, S., Xin, X., Jianxin, Y., Fengfeng, M., & Hui, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.041 · Cited by 57
Hibbeln, J. R., & Gow, R. V. (2014) · Military Medicine · doi:10.7205/milmed-d-14-00153 · Cited by 53
A phase-specific neuroimmune model of clinical depression
Eyre, H. A., Stuart, M. J., & Baune, B. T. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.011 · Cited by 60
Novel investigational drugs targeting IL-6 signaling for the treatment of depression
Fonseka, T. M., McIntyre, R. S., Soczynska, J. K., & Kennedy, S. H. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.998334 · Cited by 54
Gawali, N. B., Bulani, V. D., Chowdhury, A. A., Deshpande, P. S., Nagmoti, D. M., & Juvekar, A. R. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.07.004 · Cited by 60
Hashimoto’s thyroiditis induces neuroinflammation and emotional alterations in euthyroid mice
Cai, Y., Wang, F., Chen, Z.-X., Li, L., Fan, H., Wu, Z., Ge, J., Hu, W., Wang, Q., & Zhu, D.-F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1341-z · Cited by 58
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology
Gamble-George, J. C., Baldi, R., Halladay, L., Kocharian, A., Hartley, N., Silva, C. G., Roberts, H., Haymer, A., Marnett, L. J., Holmes, A., et al. (2016) · eLife · doi:10.7554/elife.14137 · Cited by 55
Maes, M. H. J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9326-6 · Cited by 59
Munshi, S., Parrilli, V., & Rosenkranz, J. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112024 · Cited by 61
Belge, J.-B., van Diermen, L., Sabbe, B., Parizel, P. M., Morrens, M., Coppens, V., Constant, E., de Timary, P., Sienaert, P. A., Schrijvers, D. L., et al. (2020) · Neuropsychobiology · doi:10.1159/000506133 · Cited by 57
Depression and Inflammation: Disentangling a Clear Yet Complex and Multifaceted Link
Amodeo, G., Trusso, M. A., & Fagiolini, A. M. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000236 · Cited by 70
The treatment of depression — searching for new ideas
Stachowicz, K., & Sowa-Kućma, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.988648 · Cited by 66
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53
“[42] reported similar findings in a 6-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy of adjunctive celecoxib (400 mg/d) with reboxetine (flexible-dose range, 4–10 mg/d) in MDD patients (N=40).”
BackgroundCo-Morbidity between Cardiovascular Pathology and Depression: Role of Inflammation
Halaris, A. E. (2013) · Modern trends in psychiatry · doi:10.1159/000343981 · Cited by 53
Low on energy? An energy supply-demand perspective on stress and depression
Østergaard, L., Jørgensen, M. B., & Knudsen, G. M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.08.007 · Cited by 57
Infectious Diseases and Mental Health
Müller, N. (2015) · Key Issues in Mental Health · doi:10.1159/000365542 · Cited by 45
Self-citationStatins in the treatment of depression: Hype or hope?
Köhler-Forsberg, O., Otte, C., Gold, S. M., & Østergaard, S. D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107625 · Cited by 51
Litteljohn, D., Mangano, E. N., & Hayley, S. P. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06371.x · Cited by 54
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
Haarman, B. C. M., der Lek, R. F. R., Burger, H., Netkova, M., Drexhage, R. C., Bootsman, F., Mesman, E., Hillegers, M. H. J., Spijker, A. T., Hoencamp, E., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12142 · Cited by 54
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
Self-citationOf depression and immunity: does sex matter?
Pitychoutis, P. M., & Papadopoulou-Daifoti, Z. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000465 · Cited by 50
Kobrosly, R. W., & van Wijngaarden, E. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.10.005 · Cited by 57
Nitric oxide: Antidepressant mechanisms and inflammation
Ghasemi, M. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.004 · Cited by 54
Salo, K. I., Scharfen, J., Wilden, I. D., Schubotz, R. I., & Holling, H. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01241 · Cited by 56
Brain Protection in Schizophrenia, Mood and Cognitive Disorders
Ritsner, M. S. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5 · Cited by 51
Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?
Baune, B. T. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000140 · Cited by 47
Huckans, M. S., Fuller, B. E., Chalker, A. L. N., Adams, M. K. M., & Loftis, J. M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00178 · Cited by 57
Liu, X., Luo, L., Bin-bin, L., Li, J., Geng, D., Liu, Q., & Yi, L. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.03.001 · Cited by 50
Ogawa, S., & Kunugi, H. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225212 · Cited by 52
Kranaster, L., Hoyer, C., Aksay, S. S., Bumb, J. M., Müller, N., Zill, P., Schwarz, M., & Sartorius, A. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1355473 · Cited by 52
Self-citationInflammatory pathophysiological mechanisms implicated in postpartum depression
Zhu, J., Jin, J., & Tang, J. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.955672 · Cited by 54
Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gędek, A., Szular, Z., Antosik-Wójcińska, A. Z., Mierzejewski, P., & Dominiak, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103497 · Cited by 49
IL-8 and the innate immunity as biomarkers in acute child and adolescent psychopathology
Gariup, M., González, A., Lázaro, L., Torres, F., Serra‐Pages, C., & Morer, Á. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.08.017 · Cited by 51
Baune, B. T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_19 · Cited by 50
Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism
Hafizi, S., Tabatabaei, D., & Lai, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00849 · Cited by 49
Litteljohn, D., Cummings, A., Brennan, A., Gill, A., Chunduri, S., Anisman, H., & Hayley, S. P. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.12.001 · Cited by 49
Interleukin-4 Is a Participant in the Regulation of Depressive-like Behavior
Wachholz, S., Knorr, A., Mengert, L., Plümper, J., Sommer, R., Juckel, G., & Friebe, A. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.020 · Cited by 45
Antidepressant psychopharmacology: is inflammation a future target?
Benedetti, F., Zanardi, R., & Mazza, M. G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000403 · Cited by 45
Piser, T. M. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.02.006 · Cited by 50
Krause, D., Myint, A.-M., Schuett, C., Musil, R., Dehning, S., Cerovecki, A., Riedel, M. J., Arolt, V., Schwarz, M., & Müller, N. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00016 · Cited by 46
Self-citationPoudel‐Tandukar, K., Bertone‐Johnson, E. R., Palmer, P. H., & Poudel, K. C. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.06.004 · Cited by 48
Tang, S. W., Helmeste, D., & Leonard, B. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.639800 · Cited by 42
Mitochondria: A Connecting Link in the Major Depressive Disorder Jigsaw
Sharma, S., & Akundi, R. S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180302120322 · Cited by 46
Prostaglandins as the Agents That Modulate the Course of Brain Disorders
Famitafreshi, H., & Karimian, M. (2020) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s240800 · Cited by 58
Duarte-Silva, E. P., de Melo, M. G., Maes, M. H. J., Filho, A. J. M. C., Macêdo, D. S., & Peixoto, C. A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110351 · Cited by 49
Hang, X., Zhang, Y., Li, J., Li, Z., Zhang, Y., Ye, X., Tang, Q., & Sun, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.691200 · Cited by 47
Alamdarsaravi, M., Ghajar, A., Noorbala, A.-A., Arbabi, M., Emami, A., Shahei, F., Mirzania, M., Jafarinia, M., Afarideh, M., & Akhondzadeh, S. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.05.029 · Cited by 43
“…nonsteroidal anti-inflammatory drug that acts via the selective inhibition of cyclooxygenase (COX)-2, has shown promising outcomes in several psychiatric diorders, including autistic disorder (Asadabadi et al., 2013), schizophrenia (Akhondzadeh et al., 2007), and depression (Müller et al., 2006a).”
BackgroundYao, Y., Huang, H., Yang, Y., & Guo, J. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.12.047 · Cited by 43
Bipolar and panic disorders may be associated with hereditary defects in the innate immune system
Foldager, L., Köhler‐Forsberg, O., Steffensen, R., Thiel, S., Kristensen, A. S., Jensenius, J. C., & Mors, O. N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.017 · Cited by 46
Woo, H. I., Lim, S.-W., Myung, W., Kim, D. K., & Lee, S.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0123-0 · Cited by 42
Ventorp, F., Gustafsson, A., Träskman-Bendz, L., Westrin, Å., & Ljunggren, L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140052 · Cited by 42
Krause, D., Riedel, M. J., Müller, N., Weidinger, E., Schwarz, M., & Myint, A.-M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0112-6 · Cited by 46
Self-citationEffect of celecoxib on improving depression: A systematic review and meta-analysis
Wang, Z., Wu, Q., & Wáng, Q. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i22.7872 · Cited by 42
Caspase 1 deficiency reduces inflammation-induced brain transcription
Mastronardi, C., Whelan, F., Yildiz, O. A., Hannestad, J., Elashoff, D., McCann, S. M., Licinio, J., & Wong, M.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701366104 · Cited by 42
Bipolar disorder: candidate drug targets
Zarate, C. A., & Manji, H. K. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20042 · Cited by 45
Huckans, M. S., Fuller, B. E., Olavarria, H., Sasaki, A. W., Chang, M., Flora, K. D., Kolessar, M., Kříž, D., Anderson, J. R., Vandenbark, A. A., et al. (2013) · Brain and Behavior · doi:10.1002/brb3.200 · Cited by 49
Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression
Businaro, R., Vauzour, D., Sarris, J. J., Münch, G. W., Gyengési, E., Brogelli, L., & Zuzarte, P. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.669846 · Cited by 45
Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?
García-Bueno, B., Pérez-Nievas, B. G., & Leza, J. C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000970 · Cited by 41
CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice
Onaka, Y., Shintani, N., Nakazawa, T., Haba, R., Ago, Y., Wang, H., Kanoh, T., Hayata‐Takano, A., Hirai, H., Nagata, K., et al. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.013 · Cited by 42
Herkenham, M. A., & Kigar, S. L. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.003 · Cited by 42
Baldwin, D. S., Hou, R. H., Gordon, R., Huneke, N. T. M., & Garner, M. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0423-2 · Cited by 41
Arakawa, K., Arakawa, H., Hueston, C. M., & Deak, T. (2014) · Neuroendocrinology · doi:10.1159/000368606 · Cited by 40
Mohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015592215 · Cited by 39
Zhang, K., Liu, R., Gao, Y., Ma, W., & Shen, W. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s274778 · Cited by 39
Proinflammatory cytokines and neuropeptides in psoriasis, depression, and anxiety
Keenan, E. L., & Granstein, R. D. (2025) · Acta Physiologica · doi:10.1111/apha.70019 · Cited by 43
Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression
Noto, C., Rizzo, L. B., Mansur, R. B., McIntyre, R. S., Maes, M., & Brietzke, E. (2014) · Neuroimmunomodulation · doi:10.1159/000356549 · Cited by 38
Husain, M. I., Chaudhry, I. B., Rahman, R. R., Hamirani, M. M., Qurashi, I., Khoso, A. B., Deakin, J. F., Husain, N., & Young, A. H. (2015) · Trials · doi:10.1186/s13063-015-0933-5 · Cited by 37
Aponso, M., Patti, A. F., & Bennett, L. E. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112469 · Cited by 44
Inflammation, Dopaminergic Brain and Bilirubin
Jayanti, S. D., Verde, C. D., Tiribelli, C., & Gazzin, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411478 · Cited by 44
Acute pain management in patients with fibromyalgia and other diffuse chronic pain syndromes
Pogatzki-Zahn, E. M., Englbrecht, J. S., & Schug, S. A. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32833037d2 · Cited by 43
Antidepressant-like effect of celecoxib piroxicam in rat models of depression
Santiago, R. M., Barbiero, J. K., Martynhak, B. J., Boschen, S. L., da Silva, L. M., Werner, M. F. D. P., Cunha, C. D., Andreatini, R., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1159-5 · Cited by 43
Smith, R. S., Alkozei, A., Killgore, W. D. S., & Lane, R. D. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.011 · Cited by 42
Kowalczyk, M., Szemraj, J., Bliźniewska, K., Maes, M., Berk, M., Su, K.-P., & Gałecki, P. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.05.022 · Cited by 38
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Sousa, F. S. S., Birmann, P. T., Bampi, S. R., Fronza, M. G., Balaguez, R. A., Alves, D. A. C., Leite, M. R., Nogueira, C. W., Brüning, C. A., & Savegnago, L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.028 · Cited by 41
Chronic Administration of Lamotrigine Downregulates COX-2 mRNA and Protein in Rat Frontal Cortex
Lee, H., Ertley, R. N., Rapoport, S. I., Bazinet, R. P., & Rao, J. S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9526-3 · Cited by 44
Taler, M., Bar, M., Korob, I., Lomnitski, L., Baharav, E., Grunbaum-Novak, N., Weizman, A., & Gil‐Ad, I. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.12.003 · Cited by 42
The Neuro‐Immune Axis: Prospect for Novel Treatments for Mental Disorders
Kraneveld, A. D., de Theije, C. G. M., van Heesch, F., Borre, Y., de Kivit, S., Olivier, B., Korte, M., & Garssen, J. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12154 · Cited by 37
Comorbidity of mental and physical disorders
(2014) · Key Issues in Mental Health · doi:10.1159/isbn.978-3-318-02604-7 · Cited by 37
Zhou, Z., Cheng, Y., Zou, Z., Ge, B.-C., Yu, H. M., Huang, C., Wang, H., Yang, X., & Xu, J. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00271 · Cited by 38
Liu, P., Bai, X., Zhang, T., Zhou, L., Li, J., & Zhang, L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.64 · Cited by 38
The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome.
Dell’Osso, L., Bazzichi, L. M., Baroni, S., Falaschi, V., Conversano, C., Carmassi, C., & Marazziti, D. (2015) · PubMed · Cited by 46
Müller, N., & Bechter, K. (2013) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2013.04.004 · Cited by 37
Self-citation
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.